Stockscreener 앱 받기
31.67
1.25%
-0.40
시간 외 거래:
31.67
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
Published on: 2026-02-25 12:19:59 - baoquankhu1.vn
Published on: 2026-02-24 09:21:42 - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief By Investing.com - Investing.com South Africa
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch - Yahoo Finance
IDYA: Darovasertib's phase 3 PFS readout is imminent, with accelerated approval filing expected this year - TradingView
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit - Yahoo Finance
Can IDEAYA Biosciences Inc reach all time highs this yearWeekly Stock Analysis & High Accuracy Trade Signal Alerts - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief - Investing.com
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer - TradingView
AbbVie cancer R&D leader takes charge of IDEAYA’s drug pipeline - Stock Titan
Is IDEAYA Biosciences Inc. forming a breakout patternWeekly Risk Summary & Consistent Growth Equity Picks - mfd.ru
What’s the analyst consensus on IDEAYA Biosciences Inc.Earnings Risk Summary & Weekly Stock Breakout Alerts - mfd.ru
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating - Investing.com
Wedbush Adjusts Price Target on IDEAYA Biosciences to $52 From $49, Maintains Outperform Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on IDEAYA (IDYA) Feb 18, 2026 - Meyka
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Published on: 2026-02-17 23:06:22 - mfd.ru
Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating - marketscreener.com
Ideaya Biosciences earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Finviz
Ideaya Biosciences Q4 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Net Loss $0.94 a Share, vs. FactSet Est of $1.05 Loss - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q4 Revenue $10.9M, vs. FactSet Est of $6.3M - marketscreener.com
IDEAYA Biosciences Q4 Loss Declines - Nasdaq
What is IDEAYA Biosciences Inc. s P E ratio telling usJuly 2025 Trends & Verified Swing Trading Watchlists - mfd.ru
(IDYA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is IDEAYA Biosciences Inc. benefiting from innovation trendsJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
What is IDEAYA Biosciences Inc.’s book value per share2025 EndofYear Setup & Smart Swing Trading Techniques - mfd.ru
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Candriam S.C.A. - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A 54% Potential Upside in the Precision Medicine Oncology Space - DirectorsTalk Interviews
Citizens reiterates Market Outperform rating on Ideaya Biosciences stock By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA): Unpacking The 46.63% Potential Upside In Precision Oncology - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by New York State Common Retirement Fund - MarketBeat
Liquidity Mapping Around (IDYA) Price Events - Stock Traders Daily
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - MEXC
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance
AlphaQuest LLC Has $1.12 Million Stock Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events – Company Announcement - Financial Times
Institution Moves: Is IDEAYA Biosciences Inc benefiting from innovation trends2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback - Yahoo Finance
Knights of Columbus Asset Advisors LLC Invests $934,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Grants 44,200 Stock Options to New Employee - intellectia.ai
Ideaya Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
New IDEAYA hire receives 44,200 stock options in Nasdaq inducement grant - stocktitan.net
Forecast Cut: Will IDEAYA Biosciences Inc benefit from geopolitical trendsWatch List & Consistent Income Trade Recommendations - baoquankhu1.vn
What are IDEAYA Biosciences Inc.’s recent SEC filings showingIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Potential 44.88% Upside Fuels Investor Interest - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Weekly Trades: What chart patterns are forming on IDEAYA Biosciences IncMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Why (IDYA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Street Watch: What is IDEAYA Biosciences Inc. s P E ratio telling usQuarterly Risk Review & Short-Term Swing Trade Alerts - baoquankhu1.vn
Sectors Review: Whats the beta of IDEAYA Biosciences Inc stockJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
RBC Raises Price Target on IDEAYA Biosciences to $45 From $41, Keeps Outperform, Speculative Risk - marketscreener.com
IDEAYA Biosciences (IDYA) Stock Analysis: A Promising Upside of 38.69% in Precision Medicine - DirectorsTalk Interviews
Winners Losers: Is IDEAYA Biosciences Inc subject to activist investor interestQuarterly Market Summary & AI Driven Stock Reports - baoquankhu1.vn
Ideaya Biosciences advances with IDE892 study targeting MTAP-deleted tumors - MSN
IDEAYA Biosciences, Inc. $IDYA Stake Lifted by SG Americas Securities LLC - MarketBeat
1.52%
1.68%
자본화:
|
볼륨(24시간):